CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lakefront Biotherapeutics NV is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lakefront Biotherapeutics NV
Generaal De Wittelaan L11 A3
Phone: +32 15342900p:+32 15342900 MALINES (MECHELEN), 2800  Belgium Ticker: LKFTLKFT
Business Summary
Lakefront Biotherapeutics NV is a Belgium-based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal-making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical-stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in-house cell therapy platforms. It builds a portfolio of clinical-stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Executive Director HenryGosebruch 54 5/12/2025 5/12/2025
Chief Financial Officer Aaron L.Cox 44 7/7/2025 7/7/2025
Chief Human Resources Officer TaniaPhilipp 3/4/2026 3/4/2026
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cellpoint BV Biopartner 5 Oegstgeest ZH Netherlands

Business Names
Business Name
0JXZ
Argenta Discovery 2009 Ltd.
B.V. GLPG US Holding Inc.
20 additional Business Names available in full report.

General Information
Number of Employees: 452 (As of 12/31/2025)
Outstanding Shares: 65,897,071 (As of 3/31/2026)
Stock Exchange: AMS
Fax Number: +32 15342901


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026